none19noNo abstract available.mixedS. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Rondoni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. BaccaraniS. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Rondoni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccaran
cofinanced by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). Inn-IND...
Dasatinib and nilotinib are tyrosine kinase inhibitors (TKIs) developed to overcome imatinib resista...
none9noNAmixedSoverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; R...
none19noThe emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Phil...
The treatment outcome and development of new mutations in patients with imatinib- and/or nilotinib-f...
The BCR-ABL T315I mutation causes resistance to imatinib, nilotinib and dasatinib in chronic myeloid...
none6The disease burden in chronic myeloid leukemia (CML) is linked to the activity of its chimeric ...
open10noThis study was supported by FP7 NGS-PTL agreement n° 306.242 and Progetto Regione-Università...
Raquel Vinhas,1 Alexandra Lourenço,2 Susana Santos,2 Marcos Lemos,2 Patrícia Ribeiro,2...
none18noneSOVERINI S.; GNANI A.; CATERINA DE BENEDITTIS C.; IACOBUCCI I.; VENTURI C.; PAPAYANNIDIS C...
none12nononeSimona Soverini, Caterina De Benedittis, Cristina Papayannidis, Luca Zazzeroni, Claudia ...
none4The advent of imatinib, a potent and selective inhibitor of the Bcr-Abl tyrosine kinase whose d...
PURPOSE: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor...
PURPOSE: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibito...
none8No abstract availablenoneIntermesoli T.; Castagnetti F.; Soverini S.; Bussini A.; Spinelli O.; ...
cofinanced by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). Inn-IND...
Dasatinib and nilotinib are tyrosine kinase inhibitors (TKIs) developed to overcome imatinib resista...
none9noNAmixedSoverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; R...
none19noThe emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Phil...
The treatment outcome and development of new mutations in patients with imatinib- and/or nilotinib-f...
The BCR-ABL T315I mutation causes resistance to imatinib, nilotinib and dasatinib in chronic myeloid...
none6The disease burden in chronic myeloid leukemia (CML) is linked to the activity of its chimeric ...
open10noThis study was supported by FP7 NGS-PTL agreement n° 306.242 and Progetto Regione-Università...
Raquel Vinhas,1 Alexandra Lourenço,2 Susana Santos,2 Marcos Lemos,2 Patrícia Ribeiro,2...
none18noneSOVERINI S.; GNANI A.; CATERINA DE BENEDITTIS C.; IACOBUCCI I.; VENTURI C.; PAPAYANNIDIS C...
none12nononeSimona Soverini, Caterina De Benedittis, Cristina Papayannidis, Luca Zazzeroni, Claudia ...
none4The advent of imatinib, a potent and selective inhibitor of the Bcr-Abl tyrosine kinase whose d...
PURPOSE: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor...
PURPOSE: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibito...
none8No abstract availablenoneIntermesoli T.; Castagnetti F.; Soverini S.; Bussini A.; Spinelli O.; ...
cofinanced by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). Inn-IND...
Dasatinib and nilotinib are tyrosine kinase inhibitors (TKIs) developed to overcome imatinib resista...
none9noNAmixedSoverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; R...